CalciMedica ( $CALC) Drops -27% Over 30 Days Amid Biotech Headwinds (See the latest news for any ticker on Tickeron.) CalciMedica (CALC) shares fell roughly 27% over the trailing 30 days, sliding from about $2.32 to near $1.70. The decline extended a prolonged multi-month downtrend and followed a 1-for-5 reverse stock split completed in late August. Losses came despite a Buy initiation from Guggenheim and FDA alignment on the Phase 2b Auxora trial design, underscoring lingering financing and dilution concerns. $OBIO $MTNB $ALDX $HIND
published
CalciMedica ( $CALC) Drops -27% Over 30 Days Amid Biotech Headwinds (See the latest news for any ticker on Tickeron.) CalciMedica (CALC) shares fell roughly 27% over the trailing 30 days, sliding from about $2.32 to near $1.70. The decline extended a prolonged
$CALC$OBIO$MTNB$ALDX$HIND
Latest documented BWB result
$ASML market result
Exit $ASML with $5 profit per contract on the CDS
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.